Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
- Associated Therapies
- -
EPO-4-Rhesus Study
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2019-10-02
- Target Recruit Count
- 42
- Registration Number
- NCT03104426
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Mild Encephalopathy in the Newborn Treated With Darbepoetin
- Conditions
- Interventions
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 28
- Registration Number
- NCT03071861
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
- Conditions
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 312
- Registration Number
- NCT03029208
- Locations
- 🇬🇧
GSK Investigational Site, Middlesbrough, United Kingdom
Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.
- Conditions
- Interventions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 29
- Registration Number
- NCT02987465
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 271
- Registration Number
- NCT02969655
- Locations
- 🇯🇵
GSK Investigational Site, Yamaguchi, Japan
A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 303
- Registration Number
- NCT02952092
- Locations
- 🇯🇵
Site JP00033, Aichi, Japan
🇯🇵Site JP00004, Ehime, Japan
🇯🇵Site JP00041, Ibaraki, Japan
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Registration Number
- NCT02912494
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 3554
- Registration Number
- NCT02892149
- Locations
- 🇺🇸
AMPM Research Clinic, Miami, Florida, United States
🇬🇧Research Site, Doncaster, South Yorkshire, United Kingdom
🇺🇦Research Site #1, Cherkassy, Ukraine
Erythropoietin for Management of Anemia Caused by Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Kosin University Gospel Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT02890602
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
- Conditions
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3872
- Registration Number
- NCT02876835
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.